Onyx Pharmaceuticals, Inc. to Present at UBS Warburg Global Life Sciences Conference
19 Sep 2007
Small molecular drug
EMERYVILLE, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. today announced that it will present at the UBS Global Life Sciences conference on Monday, September 24, at 9:00 a.m. Eastern Time. Interested parties may access a live webcast of the presentation at:
It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through October 27, 2007.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar has been approved for the treatment of advanced kidney cancer. For more information about Onyx's pipeline and activities, visit the company's web site at: .
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.
Onyx Pharmaceuticals, Inc.
CONTACT: Alexandra Santos of Onyx Pharmaceuticals, Inc., +1-510-597-6504
Web site:
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.